Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025.

New approval provides hospitals and clinics in the Czech Republic with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, May 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals ...

An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which is ...

Prostate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each ...

Researchers have identified a new set of urine-based biomarkers that can accurately detect both the presence and severity of ...

A simple urine test was found to detect prostate cancer with greater accuracy than the standard PSA (prostate-specific ...

An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of ...

An Evening of Hope, organized by Brave Men, Inc., a nonprofit that supports men diagnosed with prostate cancer, will take place in Wheeling, WV on May 10 to raise awareness and ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising results from a novel BMS androgen receptor antagonist and degrader in ...